Simvastatin plus rifaximin did not reduce progression to acute-on-chronic liver failure, complications from cirrhosis or risk for death in patients with decompensated cirrhosis, according to data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback